Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to three new employees to purchase an aggregate of 26,200 shares of the Company's common stock, effective as of January 2, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
舊金山，2025年1月3日（全球新聞通訊社）—— Olema Pharmaceuticals, Inc.（"Olema"或"Olema Oncology"，納斯達克：OLMA）是一家臨牀階段生物製藥公司，專注於針對乳腺癌及其他疾病的靶向療法的發現、開發和商業化。今天，公司宣佈已經向三名新員工授予了期權，允許他們總共購買26,200股公司的普通股，自2025年1月2日起生效。這些獎勵獲得了Olema董事會的薪酬委員會的批准，並根據公司的2022年誘導計劃授予，作爲新員工入職Olema的誘因，符合納斯達克上市規則5635(c)(4)。
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $5.57 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on January 2, 2025. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.
這些期權在四年內逐步歸屬，其中25%在該員工的歸屬開始日期的第一週年歸屬，剩餘部分在接下來的三年內按36個相等的月度分期歸屬，前提是該員工在這些歸屬日期時持續受僱於Olema。這些期權的期限爲10年，行使價格爲每股5.57美元，等於2025年1月2日納斯達克所報告的公司普通股的最後成交價格。這些期權受Olema Pharmaceuticals, Inc. 2022年誘導計劃的條款約束。
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema根據納斯達克上市規則5635(c)(4)提供此信息。
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at .
關於 Olema 腫瘤學
Olema腫瘤學是一家臨牀階段生物製藥公司，致力於改變治療標準，提高乳腺癌患者及其他患者的治療效果。Olema正在利用我們對內分泌驅動癌症、核受體和獲得性支撐位機制的深入理解，推進一系列新療法。我們的領先產品候選藥物palazestrant（OP-1250）是一種專有的、可口服的完全雌激素受體拮抗劑（CERAN）和選擇性雌激素受體降解劑（SERD），目前正在進行名爲OPERA-01的第三階段臨牀試驗。此外，Olema還在開發一種有效的KAT6抑制劑（OP-3136）。Olema總部位於舊金山，在馬薩諸塞州的劍橋有業務。欲了解更多信息，請訪問我們。
Media and Investor Relations Contact
Courtney O'Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
媒體和投資者關係聯繫
考特尼·奧科內克
企業通信副總裁
Olema Oncology
media@olema.com
譯文內容由第三人軟體翻譯。